March 4, 2022: We write today to follow up on your response to several requests for information at the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) Medical Device User Fee Amendments (MDUFA V) stakeholders meeting on February 28, 2022.
Read More »On Health Policy
NCHR Comments on Screening for Obstructive Sleep Apnea in Adults
April 25, 2022. Despite the recent increase in obstructive sleep apnea (OSA), we agree with the “I” grade recommendation for OSA screening in asymptomatic adults or those with unrecognized symptoms, as there is currently insufficient evidence to assess the benefits and harms of screening.
Read More »NCHR Comments on the MDUFA V Commitment Letter
April 21, 2022: NCHR would like to express our substantial concerns with the overall process as well as the shortcomings of the Commitment letter.
Read More »NCHR Comments on the Proposed 2022 Center for Disease Control (CDC) Clinical Practice Guideline for Prescribing Opioids
April 11, 2022: We commend the CDC for their continued efforts to reduce opioid use. However, we are very concerned that the impact of the Box 1 Guideline as currently written will be very harmful to patients.
Read More »NCHR Comments on the Development of Non-Opioid Analgesics for Acute Pain
April 11, 2022. In light of the ongoing opioid epidemic, we commend FDA’s goal of fostering the development of non-addictive alternatives to opioids for managing acute pain, and thereby decreasing exposure to opioids and preventing new addiction.
Read More »